5-Amino-1MQ

What 5-Amino-1MQ is

5-Amino-1MQ, formally named 5-amino-1-methylquinolinium, is a synthetic small molecule belonging to the quinolinium salt chemical class ^[1]. It is not a peptide in the classical sense; it is a low-molecular-weight, water-soluble, membrane-permeable organic compound that crosses cell membranes to act on an intracellular enzyme target ^[2]. Despite its classification in many research catalogues alongside peptides, its mechanism and structure are distinct from amino-acid-based compounds ^[3].

The compound was developed by Neelakantan, Watowich, and colleagues at the University of Texas as part of a medicinal-chemistry programme aimed at producing selective, cell-active inhibitors of NNMT ^[1][4]. Research interest in NNMT as a therapeutic target accelerated following a landmark 2014 Nature paper by Kraus et al., which demonstrated that NNMT silencing in white adipose tissue protected diet-induced obese mice from weight gain through increased energy expenditure—without reducing food intake ^[5]. Structure-activity relationship (SAR) studies then identified 5-amino-1MQ as one of the more potent and selective analogues in the quinolinium series, with confirmed on-target engagement in cell culture models ^[4][6].

What it is being researched for

1. Obesity and adipose tissue metabolism

NNMT is overexpressed in the white adipose tissue (WAT) of obese animals and in human visceral adipose tissue of morbidly obese individuals, and its elevated activity is mechanistically linked to depleted cellular NAD⁺ and SAM pools ^[5][7]. The foundational Kraus et al. Nature study showed that NNMT knockdown in WAT and liver resulted in significantly reduced relative adiposity in mice without any change in food intake, implicating increased energy expenditure as the driver ^[5]. Subsequent pharmacological work with 5-amino-1MQ confirmed that small-molecule NNMT inhibition can reverse diet-induced obesity in rodent models, reducing fat mass without affecting lean mass or food intake ^[4][8]. In cell culture, 5-amino-1MQ suppresses lipid accumulation during preadipocyte differentiation and reduces expression of key adipogenic transcription factors, providing a mechanistic account of its anti-adipogenic effects ^[6].

2. NAD⁺ salvage and cellular energy metabolism

NNMT competes directly with the NAD⁺ salvage pathway by converting nicotinamide—a key NAD⁺ precursor—irreversibly to 1-methylnicotinamide (1-MNA), thereby diverting it away from NAD⁺ biosynthesis ^[5][9]. By blocking this diversion, 5-amino-1MQ treatment in differentiated adipocytes produced a concentration-dependent increase in intracellular NAD⁺ levels of approximately 1.2–1.6-fold relative to controls, with concurrent elevation of SAM ^[1][10]. These changes converge on downstream metabolic regulators including sirtuin-1 (SIRT1), whose deacetylase activity depends on available NAD⁺ ^[7][9]. The compound has therefore been studied as an indirect means to support cellular NAD⁺ pools in metabolically stressed tissues, complementing research on direct NAD⁺ precursor supplementation strategies ^[10].

3. Skeletal muscle aging and regeneration

NNMT protein is elevated roughly three-fold in aged skeletal muscle compared to young muscle, and this overexpression is associated with reduced NAD⁺ availability and impaired muscle stem cell (satellite cell) function ^[4][11]. A study by Neelakantan and colleagues in Biochemical Pharmacology demonstrated that NNMT inhibition with a 5-amino-1MQ-class compound reactivated senescent satellite cells and improved regenerative capacity in aged mice following injury, with peak tetanic torque approximately 70% higher than in vehicle-treated controls ^[11][4]. A later Scientific Reports paper by Dimet-Wiley and colleagues from the University of Texas Medical Branch further showed that 5-amino-1MQ improved grip strength in aged mice to a greater degree than rigorous exercise training alone, and the combination of treatment with exercise produced sustained enhancements in daily running distance that did not taper off as they did with exercise alone ^[12].

4. Epigenetics and the SAM methylation sink

NNMT is one of the largest consumers of the universal methyl donor S-adenosylmethionine (SAM) in adipose tissue, creating what researchers have described as a cellular 'methylation sink' that couples metabolic reprogramming to epigenetic remodelling across DNA, RNA, and proteins ^[8][13]. By blocking NNMT, 5-amino-1MQ raises the intracellular SAM:SAH (S-adenosylhomocysteine) ratio, which can alter the activity of DNA methyltransferases and histone methyltransferases ^[7][6]. In 3T3-L1 preadipocyte models, this shift has been proposed to increase histone H3 lysine 4 methylation at adipogenic gene promoters, altering the transcriptional programme that drives preadipocyte commitment to the adipocyte lineage ^[6]. Research into this epigenetic dimension is ongoing and has implications for understanding how metabolic and gene-regulatory pathways interconnect in obesity and aging ^[8][13].

5. Oncology: NNMT overexpression in cancer

NNMT overexpression has been documented across a range of cancer types and is associated with increased tumour cell proliferation, migration, invasion, and resistance to chemotherapy ^[13][14]. Elevated NNMT activity in cancer-associated fibroblasts (CAFs) has been shown to be required to maintain the CAF phenotype in high-grade serous carcinoma, suggesting NNMT as a relevant target in the tumour microenvironment ^[15]. In Merkel cell carcinoma and osteosarcoma cell lines, treatment with 5-amino-1-methylquinolinium (5-AMQ) was evaluated for effects on cell viability, apoptosis, oxidative stress, and chemotherapy sensitivity ^[14]. This body of research positions NNMT inhibition as a candidate strategy to sensitise cancer cells to existing treatments, though this application remains at the preclinical stage ^[13][14].

6. Neurodegeneration and neurological research

Epidemiological and genetic evidence has implicated NNMT in several neurological conditions, including Parkinson's disease, schizophrenia, Alzheimer's disease, Huntington's disease, and bipolar disorder ^[9][16]. A study by Schmeisser and Parker using C. elegans demonstrated that neuronal NNMT activity modulates behaviour, lifespan, and neurodegeneration through regulation of autophagy ^[16]. A 2025 PubMed review concluded that NNMT's dual impact on epigenetic regulation—via SAM depletion—and metabolic homeostasis—via NAD⁺ disruption and sirtuin suppression—makes it a 'multifactorial therapeutic target' in neurodegenerative disease, though challenges remain in optimising blood-brain barrier penetration and cellular specificity for small-molecule NNMT inhibitors ^[9].

7. Gut microbiome interactions

A PMC-indexed 2022 study examined whether NNMT inhibition modifies the gut microbiome in the context of dietary intervention. Treatment with 5-amino-1-methylquinolinium combined with a low-fat diet promoted dramatic whole-body adiposity and weight loss in diet-induced obese mice, rapidly normalising these measures to the level of age-matched lean animals, while low-fat diet switch alone could not restore these measures in the same timeframe ^[17]. The microbiome analysis revealed that the combination of NNMT inhibition and dietary change established a distinct cecal microbiome profile, suggesting a potential interaction between NNMT-dependent metabolic pathways and the gut microbial environment ^[17]. This connection is early-stage and its mechanistic basis remains under investigation.

How it is thought to work

NNMT catalyses the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide—a form of vitamin B3—producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH) ^[5][8]. This reaction simultaneously depletes two critical cellular resources: SAM (the primary methyl donor for epigenetic modifications including DNA and histone methylation) and nicotinamide (the rate-limiting precursor to NAD⁺ via the salvage pathway) ^[7][9]. 5-Amino-1MQ occupies the nicotinamide-binding pocket of the NNMT active site as a competitive inhibitor, blocking this methyl transfer reaction ^[1][4]. In vitro selectivity studies showed that at pharmacologically relevant concentrations, the compound does not significantly inhibit related methyltransferases such as DNMT1 or PRMT3, nor does it directly affect other enzymes in the NAD⁺ salvage pathway ^[1].

The downstream consequences of NNMT blockade are twofold and linked. First, intracellular nicotinamide is preserved and re-enters the NAD⁺ biosynthesis salvage pathway, raising cellular NAD⁺ levels and restoring NAD⁺-dependent enzyme activity, most notably sirtuin-1 (SIRT1) ^[7][10]. Second, SAM is no longer consumed by NNMT, raising the SAM:SAH ratio and increasing the availability of methyl groups for histone and DNA methyltransferases, thereby shifting the epigenetic landscape of treated cells ^[6][8]. In tissues where NNMT is highly expressed—such as white adipose tissue in obese animals and aged skeletal muscle—these shifts are associated with measurable changes in gene expression, energy expenditure, and cellular differentiation programmes ^[5][4]. NNMT expression is known to vary substantially between tissues, which means the magnitude of these effects is expected to differ depending on the tissue context being studied ^[9].

Where the evidence stands

The published evidence base for 5-amino-1MQ is concentrated at the in vitro and rodent preclinical level. Cell culture studies using 3T3-L1 adipocytes and primary human adipose-derived stem cells have confirmed concentration-dependent NNMT inhibition, NAD⁺ elevation of 1.2–1.6-fold relative to controls, and suppression of lipid accumulation during adipogenesis ^[1][6]. In diet-induced obese mouse models, pharmacological NNMT inhibition reduced fat mass, improved insulin sensitivity, and increased energy expenditure without altering food intake ^[5][4][8]. In aged mouse skeletal muscle, a 5-amino-1MQ-class compound reactivated senescent satellite cells and improved regenerative capacity, while a separate study reported substantially improved grip strength when combined with exercise ^[4][12]. In oncology models, effects on cell viability, apoptosis, and chemosensitivity have been reported in Merkel cell carcinoma and osteosarcoma cell lines ^[14]. Across all these domains, the literature is largely generated by a single research group at the University of Texas, with limited independent replication to date ^[7].

Critically, no published randomised controlled trials in human subjects have been completed or reported for 5-amino-1MQ as of the time of writing ^[12][9]. Direct measurement of intracellular NAD⁺ changes following NNMT inhibition has not been published in humans, and whether the metabolic and epigenetic findings observed in rodents translate to people remains unknown ^[9]. Additional limitations include tissue-specific variability in NNMT expression—meaning effects will differ by tissue type—and the recognised challenge of achieving adequate blood-brain barrier penetration for neurological applications ^[9][16]. The overall evidence profile is mechanistically compelling but remains firmly at the preclinical stage, and the compound has no regulatory approval for any therapeutic indication.

Frequently asked questions

What is 5-amino-1MQ and is it actually a peptide?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule, not a peptide. It is a quaternary ammonium salt built on a quinolinium scaffold, chemically distinct from the amino-acid-chain compounds typically classified as peptides. It appears in research-peptide catalogues because it shares a similar research-compound regulatory status rather than a similar chemical structure.

How does 5-amino-1MQ raise NAD⁺ levels?

By blocking the enzyme NNMT, 5-amino-1MQ prevents nicotinamide—a key precursor in the NAD⁺ biosynthesis salvage pathway—from being irreversibly converted to 1-methylnicotinamide. The preserved nicotinamide can then re-enter the salvage pathway and be converted to NAD⁺. In adipocyte cell culture this has produced a roughly 1.2–1.6-fold increase in intracellular NAD⁺ relative to controls. This mechanism is indirect: the compound targets the enzyme that diverts the precursor, rather than supplying the precursor directly as NMN or NR supplements do.

What does NNMT do, and why is it a research target?

NNMT (nicotinamide N-methyltransferase) methylates nicotinamide using SAM as a methyl donor, simultaneously depleting NAD⁺ precursors and reducing the cellular pool of methyl groups available for epigenetic modifications. The enzyme is overexpressed in the white adipose tissue of obese individuals and is elevated in several cancer types and aged muscle. Because elevated NNMT activity correlates with metabolic dysfunction, impaired muscle regeneration, and certain cancers, researchers have identified it as a potential therapeutic target across these disease contexts.

Is there any human clinical trial data for 5-amino-1MQ?

No completed, published randomised controlled trials in humans have been reported for 5-amino-1MQ as of 2026. All peer-reviewed evidence comes from cell culture and rodent preclinical studies. Whether the metabolic, body composition, or muscle effects observed in animals translate to humans remains scientifically unestablished.

What did the muscle aging studies find?

Preclinical studies found that NNMT protein is elevated roughly three-fold in aged skeletal muscle compared to young muscle, with corresponding reductions in NAD⁺ and satellite cell activity. A 5-amino-1MQ-class NNMT inhibitor reactivated senescent muscle stem cells and improved muscle regeneration in aged mice following injury. A subsequent Scientific Reports study from the University of Texas Medical Branch showed that the compound improved grip strength in aged mice to a greater degree than rigorous exercise training alone, with the combination of both producing sustained improvements in daily running distance.

What is the connection between 5-amino-1MQ and epigenetics?

By blocking NNMT, 5-amino-1MQ reduces the enzyme's consumption of S-adenosylmethionine (SAM), thereby raising the SAM:SAH ratio inside the cell. SAM is the primary methyl donor for DNA methyltransferases and histone methyltransferases, so preserving it alters the availability of methyl groups for these epigenetic writers. In adipocyte models this shift has been associated with changes in histone methylation at adipogenic gene promoters, potentially altering cell fate decisions, though these epigenetic effects are still being characterised.

Is 5-amino-1MQ selective, or does it affect other enzymes too?

Preclinical selectivity profiling showed that at pharmacologically relevant concentrations, 5-amino-1MQ did not significantly inhibit the related methyltransferases DNMT1 or PRMT3, nor did it directly affect other enzymes in the NAD⁺ salvage pathway. This selectivity for NNMT over other SAM-dependent methyltransferases is considered one of the compound's key pharmacological attributes and was part of the rationale for selecting it as a lead from a larger series of analogues.

What research areas beyond fat loss and muscle is 5-amino-1MQ studied for?

Beyond adipose tissue metabolism and skeletal muscle aging, NNMT inhibition—and 5-amino-1MQ specifically—is being investigated in oncology (where NNMT overexpression correlates with tumour aggression and chemotherapy resistance), in neurodegeneration (where epidemiological data links NNMT to Parkinson's disease, schizophrenia, and Alzheimer's disease), and in gut microbiome modulation (where combined dietary and NNMT-inhibitor interventions established a distinct microbial profile in obese mouse models). All of these remain at the preclinical or hypothesis-generating stage.

How does 5-amino-1MQ differ mechanistically from NMN or NR supplements?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) work by supplying additional substrate that feeds directly into the NAD⁺ biosynthesis pathway. 5-Amino-1MQ instead works upstream by blocking the enzyme that diverts nicotinamide away from that pathway. The distinction matters because 5-amino-1MQ does not add any NAD⁺ precursor; it reduces the rate at which the existing nicotinamide pool is consumed by NNMT, freeing more of it to enter the salvage pathway.

What are the main limitations of the current evidence?

The published peer-reviewed evidence is largely derived from a single research group and their collaborators, with limited independent replication to date. All efficacy evidence is preclinical—from cell lines and rodent models—and no completed human trials have been published. Additional limitations include tissue-specific variability in NNMT expression, challenges achieving blood-brain barrier penetration for neurological applications, and the unknown long-term safety profile of sustained NNMT inhibition in living organisms.

Glossary

NNMT (Nicotinamide N-methyltransferase)

A cytosolic enzyme that transfers a methyl group from SAM to nicotinamide, producing 1-methylnicotinamide and consuming both NAD⁺ precursors and methyl-donor capacity in the process.

NAD⁺ (Nicotinamide adenine dinucleotide)

A coenzyme found in all living cells that is essential for energy metabolism, DNA repair, and the regulation of sirtuin enzymes; its intracellular levels decline with age and metabolic dysfunction.

SAM (S-adenosylmethionine)

The primary methyl-group donor in the cell, required by DNA methyltransferases, histone methyltransferases, and NNMT itself; SAM availability directly influences the cell's epigenetic landscape.

SAH (S-adenosylhomocysteine)

The product formed after SAM donates its methyl group; the SAM:SAH ratio is used as an index of the cell's methylation capacity, with higher ratios indicating more available methyl groups.

1-MNA (1-methylnicotinamide)

The product of the NNMT reaction, formed when nicotinamide is methylated; its production is used as a biomarker of NNMT activity and on-target engagement in research studies.

Salvage pathway (NAD⁺)

The intracellular recycling route by which cells regenerate NAD⁺ from nicotinamide and related precursors, which is the predominant source of NAD⁺ in most mammalian tissues.

SIRT1 (Sirtuin-1)

An NAD⁺-dependent deacetylase enzyme that regulates gene expression, mitochondrial biogenesis, and cellular stress responses; its activity is proportional to intracellular NAD⁺ availability.

Muscle satellite cells (muscle stem cells)

Tissue-resident stem cells that normally repair and regenerate skeletal muscle fibre after injury; their function declines with age and is associated with reduced NAD⁺ and elevated NNMT activity in aged muscle.

References

1. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice (Neelakantan et al., PMC full text) — PMC / Biochemical Pharmacology
2. Novel Inhibitors of Nicotinamide-N-Methyltransferase for the Treatment of Metabolic Disorders — PMC / Molecules
3. Small Molecule Inhibitors of Nicotinamide N-Methyltransferase for the Treatment of Osteosarcoma and Merkel Cell Carcinoma — PMC
4. Nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle (Neelakantan et al., Biochem Pharmacol 2019) — referenced via Frontiers in Pharmacology review — Frontiers in Pharmacology (2024 review citing Neelakantan et al. 2019)
5. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Kraus et al., Nature 2014) — Nature
6. Nicotinamide N-methyltransferase (NNMT) regulates the glucocorticoid signaling pathway during the early phase of adipogenesis — PMC / Scientific Reports
7. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome — Frontiers in Pharmacology
8. NNMT and the methylation sink: integrating metabolism, epigenetics and immunity in cancer (PubMed, 2026) — PubMed / BMC Medicine
9. Nicotinamide N-methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions — PubMed
10. A systems-approach to NAD⁺ restoration (ScienceDirect, Biochemical Pharmacology 2022) — ScienceDirect / Biochemical Pharmacology
11. NAD⁺: An old but promising therapeutic agent for skeletal muscle ageing (ScienceDirect, Ageing Research Reviews 2023) — ScienceDirect / Ageing Research Reviews
12. New Insights on Muscle Strength: The Role of Inhibiting an Enzyme that Hinders NAD⁺ Synthesis (NMN.com summary of Dimet-Wiley et al., Scientific Reports) — NMN.com (reporting on Scientific Reports, Watowich lab)
13. Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions — PMC / International Journal of Molecular Sciences
14. Small Molecule Inhibitors of Nicotinamide N-Methyltransferase for the Treatment of Osteosarcoma and Merkel Cell Carcinoma (PMC 2025) — PMC
15. Potent Uncompetitive Inhibitors of Nicotinamide N-Methyltransferase (NNMT) as In Vivo Chemical Probes — PubMed / Journal of Medicinal Chemistry